세계의 아스페르길루스증 치료제 시장 2019-2023

■ 영문 제목 : Global Aspergillosis Drugs Market 2019-2023

Technavio가 발행한 조사보고서이며, 코드는 IRTNTR30404 입니다.■ 상품코드 : IRTNTR30404
■ 조사/발행회사 : Technavio
■ 발행일 : 2018년 12월 4일
■ 페이지수 : 110
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일
■ 조사대상 지역 : 글로벌, 미주, 유럽, 아시아
■ 산업 분야 : 의료
■ 판매가격 / 옵션 (부가세별도)
Single User (1명 열람용)USD2,500 ⇒환산₩2,950,000견적의뢰/주문/질문
Five User (5명 열람용)USD3,000 ⇒환산₩3,540,000견적의뢰/주문/질문
Enterprise License (전사내 공유가능)USD4,000 ⇒환산₩4,720,000견적의뢰/구입/질문
가격옵션 설명
- 지불하실 금액은 상기 원화금액에 부가세(10%)를 더한 금액입니다.
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제이며, 납품후 5일이내에 청구서를 발행/송부합니다.
본 조사보고서는 아스페르길루스증 치료제의 세계시장에 대해서 조사분석한 자료로서, 아스페르길루스증 치료제의 세계시장규모, 시장동향, 시장환경 분석, 세그멘트별 분석, 지역별 분석 (미주, 유럽, 아시아), 관련기업 정보등이 포함되어 있습니다.
■ 보고서 개요

About this marketStrategic alliances to trend in the market. Pharmaceuticaq companies are working in collaboration for the development of medications for the treatment of aspergillosis. These alliances can enhance R&D activities for new drugs for the management of aspergillosis. Such alliances help companies to develop therapeutic drugs which can be introduced quickly into the market. Technavio’s analysts have predicted that the aspergillosis drugs market will register a CAGR of almost 4% by 2023.
Market Overview
Increasing awareness of aspergillosis
To create awareness about aspergillosis and other diseases and treatment options and avoid delay in diagnosis, the Aspergillus Website, funded by the Fungal Infection Trust in partnership with the University of Manchester, was created. The site provides detailed information about the fungus Aspergillus and the diseases it causes.
Increasing popularity of generic drugs
The development of generic drugs is simple, and less time taking and also requires minimal R&D expenditure than the innovator drugs. Thus, the launch of generic drugs in lesser price than the innovator drugs id diluting and hampering the growth of the aspergillosis drugs market.
For the detailed list of factors that will drive and challenge the growth of the aspergillosis drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Astellas Pharma and Gilead the competitive environment is quite intense. Factors such as the rising strategic alliances and the increasing awareness of aspergillosis, will provide considerable growth opportunities to aspergillosis drugs manufactures. Astellas Pharma, Gilead, Johnson & Johnson Services, Merck Sharp & Dohme, and Pfizer are some of the major companies covered in this report.

■ 보고서 목차

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Triazoles – Market size and forecast 2018-2023
• Other therapeutics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
PART 10: VENDOR LANDSCAPE
• Market drivers
• Market challenges
PART 11: TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Astellas Pharma
• Gilead
• Johnson & Johnson Services
• Merck Sharp & Dohme
• Pfizer
PART 14: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global infectious disease therapeutics market
Exhibit 03: Segments of global infectious disease therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Triazoles – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Triazoles – Year-over-year growth 2019-2023 (%)
Exhibit 22: Other therapeutics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other therapeutics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Impact of drivers and challenges
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Astellas Pharma – Vendor overview
Exhibit 47: Astellas Pharma – Business segments
Exhibit 48: Astellas Pharma – Organizational developments
Exhibit 49: Astellas Pharma – Geographic focus
Exhibit 50: Astellas Pharma – Key offerings
Exhibit 51: Astellas Pharma – Key customers
Exhibit 52: Gilead – Vendor overview
Exhibit 53: Gilead – Business segments
Exhibit 54: Gilead – Organizational developments
Exhibit 55: Gilead – Geographic focus
Exhibit 56: Gilead – Key offerings
Exhibit 57: Gilead – Key customers
Exhibit 58: Johnson & Johnson Services – Vendor overview
Exhibit 59: Johnson & Johnson Services – Business segments
Exhibit 60: Johnson & Johnson Services – Organizational developments
Exhibit 61: Johnson & Johnson Services – Geographic focus
Exhibit 62: Johnson & Johnson Services – Segment focus
Exhibit 63: Johnson & Johnson Services – Key offerings
Exhibit 64: Johnson & Johnson Services – Key customers
Exhibit 65: Merck Sharp & Dohme – Vendor overview
Exhibit 66: Merck Sharp & Dohme – Business segments
Exhibit 67: Merck Sharp & Dohme – Organizational developments
Exhibit 68: Merck Sharp & Dohme – Geographic focus
Exhibit 69: Merck Sharp & Dohme – Segment focus
Exhibit 70: Merck Sharp & Dohme – Key offerings
Exhibit 71: Merck Sharp & Dohme – Key customers
Exhibit 72: Pfizer – Vendor overview
Exhibit 73: Pfizer – Business segments
Exhibit 74: Pfizer – Organizational developments
Exhibit 75: Pfizer – Geographic focus
Exhibit 76: Pfizer – Segment focus
Exhibit 77: Pfizer – Key offerings
Exhibit 78: Pfizer – Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: List of abbreviations



■ 기재된 기업 리스트

Astellas Pharma, Gilead, Johnson & Johnson Services, Merck Sharp & Dohme, Pfizer


■ 보고서의 키워드

아스페르길루스증 치료제


■ 조사 방법

Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.

※본 조사보고서 [세계의 아스페르길루스증 치료제 시장 2019-2023] (코드 : IRTNTR30404) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 아스페르길루스증 치료제 시장 2019-2023] 에 대해서 E메일 문의는 여기를 클릭하세요.